As ERRs have been shown to be promising therapeutic targets in different cancer entities, several specific agonists and antagonists for ERR subtypes have been developed showing convincing effects in vitro (Ariazi and Jordan 2006; Du et al. 2017; Vernier et al. 2020). This evidence concerns the gene SLC7A1 and cancer.